Share
Dr. Tina Nova
Truvian Health, a leader in developing comprehensive and accessible diagnostic solutions, has appointed Tina S. Nova, Ph.D., to its Board of Directors.
Dr. Nova brings more than 20 years of exceptional leadership experience in diagnostics and biotechnology, making her a valuable addition to the company’s mission of advancing transformative healthcare.
Dr. Nova most recently served as President and CEO of Decipher Biosciences, where she drove innovation in urologic cancer diagnostics, ultimately leading to the company’s US$600 million acquisition by Veracyte in 2021. Her extensive career includes leadership roles at Molecular Stethoscope, Illumina, and Genoptix Medical Laboratory, where she co-founded the company, led it through a successful IPO, and oversaw its acquisition by Novartis AG. Earlier in her career, Dr. Nova held positions at Nanogen, Ligand Pharmaceuticals, and Hybritech.
In addition to her new role at Truvian Health, Dr. Nova serves on the boards of Azenta, Exagen, and Rady’s Children’s Institute for Genomic Medicine. She has earned numerous accolades, including the Women’s Entrepreneurship Day Pioneer Award and recognition as one of FierceBiotech’s Top 10 Women in Biotech.
Dr. Nova holds a Ph.D. in Biochemistry from the University of California, Riverside, and a Bachelor of Science in Biological Sciences with honors from the University of California, Irvine.
Her appointment reflects Truvian Health’s commitment to attracting visionary leaders to guide its mission of delivering accessible and accurate diagnostics to patients worldwide.
Related posts
